GlobeNewswire Inc.··Cadrenal Therapeutics, Inc.Cadrenal's Novel 12-LOX Inhibitor Shows Promise in Obesity and Diabetes Research
Cadrenal's 12-LOX inhibitor CAD-1005 shows preclinical promise for obesity and diabetes inflammation reduction, potentially complementing GLP-1 medications.
CVKDclinical developmentGLP-1 medications